

Anticipation of a Novel Gene Therapy Inspired by a Concept of iPS Cells

Fumiaki Uchiumi^{1,2*} and Sei-ichi Tanuma^{2,3}

¹Department of Gene Regulation, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda-shi, Chiba-ken, Japan

²Research Center for RNA Science, RIST, Tokyo University of Science, Noda-shi, Chiba-ken, Japan

³Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda-shi, Chiba-ken, Japan

Abstract

This year Nobel Prize in Physiology or Medicine was dedicated to two researches who have established and developed the study in the field of stem cells. At present, there seems to be still several problems to have to overcome before applying the techniques with iPS (induced pluripotent stem) cells to the practical use in the medical treatments. However, the concept of the iPS cells has brought a great hope not only in medicine, especially in regenerative therapies, but also in the development of new drugs. Here, from the point of view of medicine, we propose another possibility to apply the concept of iPS cells to the new therapy of diseases, such as cancer.

Keywords: Gene therapy; iPS cells; Regenerative therapy; Reprogramming of cells; Transcription factors

The principle of the establishment of iPS cells is based on the cell biology to reprogram a differentiated cell to a state that the cell can differentiate into variety of cell types [1]. Various chemical compounds will be subjected to screening systems to identify or develop drugs that induce cell pluripotency [2]. However, the establishment of the iPS cells was originally demonstrated by the introduction of the set of four gene expression vectors into somatic cells [1,3]. It is frequently referred as Yamanaka factors, comprising of OCT3/4, SOX2, KLF4, and c-MYC. And it should be noted that all the encoded proteins are known as functional transcription factors (TFs) with DNA binding activities [4]. The concept of establishing iPS cells is extremely important to have indicated that only four TFs are required to manipulate cells convert into iPS cells, implying that certain alterations of transcriptional state in a cell can reinforce the cell to go back to its progenitors.

Up to present, a lot of efforts have been taken on the studies of cancer, and it was revealed that many factors, including proto-oncogene or tumor suppressor gene products and signal transduction proteins, are involved in the generation of tumors [5]. Given that cancer cells are originated from healthy cells, isn't it possible to reverse the history of cells into healthy state by introducing several TF-encoding gene expression vectors? Sooner or later, comprehensive studies of cancer by genomics or proteomics will indicate right combinations of the TF-encoding genes to regenerate normal cells from cancer cells. If

introduction of these TF-encoding genes will make malignant cancer cells to stop growth and to go back into its progenitor like state, the only treatment that physicians need to do for the patients will be to deliver the TF-encoding gene expression vectors into cancer cells. This might be practically possible after the establishment of the gene-transfer system that is suitable for each individual cancer cell.

This proposal for the cancer therapy is only an example from the unlimited iPS cell-based concept. All researchers including us, especially who are studying life sciences, had better applaud the establishment of iPS cells that will make impossible to possible.

References

1. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126: 663-676.
2. Barbaric I, Gokhale PJ, Andrews PW (2010) High-content screening of small compounds on human embryonic stem cells. *Biochem Soc Trans* 38: 1046-1050.
3. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131: 861-872.
4. Papp B, Plath K (2011) Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. *Cell Res* 21: 486-501.
5. Samuels Y, Bardelli A, López-Otín C (2011) The cancer genome. In: DeVita Jr VT, Lawrence TS, Rosenberg SA (Eds). *Cancer, Principles & Practice of Oncology, Primer of the Molecular Biology of Cancer*, Lippincott Williams & Wilkins, a Wolters Kluwer business, Philadelphia 2-25.

***Corresponding author:** Fumiaki Uchiumi, Department of Gene Regulation, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo University of Science, 2641 Yamazaki, Noda-shi, Chiba-ken 278-8510, Japan, Tel: +81-4-7121-3616; Fax: +81-4-7121-3608; E-mail: uchiumi@rs.noda.tus.ac.jp

Received November 23, 2012; **Accepted** December 17, 2012; **Published** December 21, 2012

Citation: Uchiumi F, Tanuma S (2012) Anticipation of a Novel Gene Therapy Inspired by a Concept of iPS Cells. *Pharmaceut Anal Acta* 3: 196. doi:10.4172/2153-2435.1000196

Copyright: © 2012 Uchiumi F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.